The biological role of mucins in cellular interactions and immune regulation: Prospects for cancer immunotherapy

Molecular Medicine Today

Volumn 4, Issue 9, 1998, Pages 397-403

  Agrawal, Babita ^a   Gendler, Sandra J ^b   Longenecker, B Michael ^c  

^a Biomira Inc   (Canada)

^b MAYO GRADUATE SCHOOL   (United States)

^c Biomira   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MUCIN;

ANTIBODY RESPONSE; CANCER IMMUNOTHERAPY; CELL ADHESION; CELL INTERACTION; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HUMAN; IMMUNOREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; CA-15-3 ANTIGEN; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MOLECULAR SEQUENCE DATA; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0031665243     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(98)01322-7     Document Type: Review

References (48)

1. Devine P.L., McKenzie I.F.C. Mucins: structure, function, and associations with malignancy. BioEssays. 14:1992;619-625.
2. Gendler S.J.et al. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem. 265:1990;15286-15293.
3. Bramwell M.E., Wiseman G., Shotton D.M. Electron-microscopic studies of the CA antigen, epitectin. J. Cell Sci. 86:1986;249-261.
4. Hanisch F.G., Stadie T.R., Deutzmann F., Peter-Katalinic J. MUC1 glycoforms in breast cancer cell line T47D as a model for carcinoma-associated alterations of O-glycosylation. Eur. J. Biochem. 236:1996;318-327.
5. Burchell J.et al. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 47:1987;5476-5482.
6. Gendler S.J., Spicer A.P. Epithelial mucin genes. Annu. Rev. Physiol. 57:1995;607-634.
7. Yamamoto M., Bharti A., Li Y., Kufe D. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J. Biol. Chem. 272:1997;12492-12494.
8. Parry G.et al. Determination of apical membrane polarity in mammary epithelial cell cultures: the role of cell-cell, cell-substratum, and membrane-cytoskeleton interactions. Exp. Cell Res. 188:1990;302-311.
9. Zrihan-Licht S.et al. Tyrosine phosphorylation of the MUC1 breast cancer membrane proteins. Cytokine receptor-like molecules. FEBS Lett. 356:1994;130-136.
10. Mockensturm-Gardner M., Gendler S.J. The role of MUC1 at the membrane may involve transduction of a signal. Mol. Biol. Cell. 7:1996;434a.
11. Wesseling J.et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 129:1995;255-265.
12. Wesseling J., van der Valk S.W., Hilkens J. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol. Biol. Cell. 7:1996;565-577.
13. Hayes D.F., Silberstein D.S., Rodrique S.W., Kufe D.W. DF3 antigen, a human epithelial cell mucin, inhibits adhesion of eosinophils to antibody-coated targets. J. Immunol. 145:1990;962-970.
14. Zhang K., Sikut R., Hansson G.C. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell. Immunol. 166:1997;158-165.
15. Zhang K., Baeckstrom D., Brevinge H., Hansson G.C. Comparison of sialyl-Lewis a-carrying CD43 and MUC1 mucins secreted from a colon carcinoma cell line for E-selectin binding and inhibition of leukocyte adhesion. Tumor Biol. 18:1997;175-187.
16. Zhang K., Baeckstrom D., Brevinge H., Hansson G.C. Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells. J. Cell. Biochem. 60:1996;538-549.
17. Regimbald L.H.et al. The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res. 56:1996;4244-4249.
18. Burchell J., Wang D., Taylor-Papadimitriou J. Detection of the tumour-associated antigens recognized by the monoclonal antibodies HMFG-1 and 2 in serum from patients with breast cancer. Int. J. Cancer. 34:1984;763-768.
19. Spicer A.P., Rowse G.J., Lidner T.K., Gendler S.J. Delayed mammary tumor progression in Muc-1 null mice. J. Biol. Chem. 270:1995;30093-30101.
20. Bresalier R.S.et al. Mucin production by human colonic carcinoma cells correlates with their metastatic potential in animal models of colon cancer metastasis. J. Clin. Invest. 87:1991;1037-1045.
21. Hilkens J.et al. Is episialin/MUC1 involved in breast cancer progression? Cancer Lett. 90:1995;27-33.
22. Nakamori S.et al. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology. 106:1994;353-361.
23. + lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol. Immunother. 42:1996;303-309.
24. MacLean G.D., Reddish M.A., Longenecker B.M. Prognostic significance of preimmunotherapy serum CA27.29 (MUC-1) mucin level after active specific immunotherapy of metastatic adenocarcinoma patients. J. Immunother. 20:1997;70-78.
25. Chan D.W.et al. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J. Clin. Oncol. 15:1997;2322-2328.
26. + activation antigens on peripheral blood PBL populations in metastatic breast and ovarian cancer patients: correlations with survival following active specific immunotherapy. Int. J. Cancer. 61:1995;470-474.
27. Alexander R.B.et al. Helper T-cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes. J. Immunother. 17:1995;39-46.
28. Barnd D.L., Lan M.S., Metzgar R.S., Finn O.J. Specific major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T-cells. Proc. Natl. Acad. Sci. U. S. A. 86:1989;7159-7163.
29. Friberg S., Lilliehook B. Evidence for non-exposed H-2 antigens in immunoresistant murine tumors. Nat. New Biol. 241:1973;112-113.
30. Sanford B.H., Codington J.F., Jeanloz R.W., Palmer P.D. Transplantability and antigenicity of two sublines of the TA3 tumor. J. Immunol. 110:1973;1233-1237.
31. Fung P.Y.S., Longenecker B.M. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine mammary adenocarcinoma (TA3-HA). Cancer Res. 51:1991;1170-1176.
32. Peat N.et al. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res. 52:1992;1954-1960.
33. Rowse G.J.et al. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 58:1998;315-321.
34. Agrawal B., Krantz M.J., Reddish M.A., Longenecker B.M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med. 4:1998;43-49.
35. Gimmi C.D.et al. Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat. Med. 2:1996;1367-1370.
36. Coventry B.J.et al. Lack of IL-2 cytokine expression despite IL-2 messenger RNA transcription in tumor infiltrating lymphocytes in primary human breast carcinoma. J. Immunol. 156:1996;3486-3492.
37. Apostolopoulos V., Osinski C., McKenzie I.F.C. MUC1 cross-reactive Galα (1,3)Gal antibodies in humans switch immune responses from cellular to humoral. Nat. Med. 4:1998;315-320.
38. Sandrin M.S., Vaughan H.A., Sing P-X., McKenzie I.F.C. Natural human anti-Galα (1,3)Gal antibodies react with human mucin peptides. Glycoconjugate J. 14:1997;97-105.
39. Liu X.et al. Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer-associated mucin, MUC-1 derived peptides. Glycoconjugate J. 12:1995;607-617.
40. Agrawal B., Reddish M.A., Longenecker B.M. In vitro induction of MUC-1 peptide specific type-1 lymphocyte and CTL responses from healthy multiparous donors. J. Immunol. 157:1996;2089-2095.
41. Reddish M.A.et al. Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer. 76:1998;817-823.
42. Rosenberg S.A.et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321-327.
43. McGuckin M.A., Devine P.L., Ramm L.E., Ward B.G. Factors effecting the measurement of tumor-associated MUC1 mucins in serum. Tumour Biol. 15:1994;33-44.
44. Hey N.A., Graham R.A., Seif M.W., Aplin J.D. The polymorphic epithelial mucin MUC1 in human endometrium is regulated with maximal expression in the implantation phase. J. Clin. Endocrinol. Metab. 78:1994;337-342.
45. + CTL activity within the human female reproductive tract. Influence of stage of the menstrual cycle and menopause. J. Immunol. 158:1997;3017-3027.
46. Takahashi T.et al. Expression of MUC-1 on myeloma cells and induction of HLA-unrestricted CTL against MUC-1 from a multiple myeloma patient. J. Immunol. 153:1994;2102-2109.
47. Braga V.M.M., Gendler S.J. Modulation of Muc-1 mucin expression in the mouse uterus during the estrus cycle, early pregnancy and placentation. J. Cell Sci. 105:1993;397-405.
48. Agrawal, B., Krantz, M.J., Parker, J. and Longenecker, B.M. Human T cells: implications for a role of Muc1 in normal immune regulation, Cancer Res. (in press).